Comparison of trypsin inhibitors in preservation solution for islet isolation. 2009

Hirofumi Noguchi, and Michiko Ueda, and Shuji Hayashi, and Naoya Kobayashi, and Teru Okitsu, and Yasuhiro Iwanaga, and Hideo Nagata, and Xiaoling Liu, and Hiroki Kamiya, and Marlon F Levy, and Shinichi Matsumoto
Transplantation Unit, Kyoto University Hospital, Kyoto 606-8507, Japan. hirofumn@baylorhealth.edu

Islet transplantation has recently emerged as an effective therapy and potential cure for type 1 diabetes mellitus. Recent reports show that the two-layer method (TLM), which employs oxygenated perfluorochemical (PFC) and University of Wisconsin (UW) solution, is superior to simple cold storage in UW for pancreas preservation in islet transplantation. Moreover, we recently reported that islet yield was significantly higher in the ET-Kyoto solution with ulinastatin (MK)/PFC preservation solution compared with the UW/PFC preservation solution in the porcine model and that the advantages of MK solution are trypsin inhibition and less collagenase inhibition. In this study, we compared ulinastatin with another trypsin inhibitor, Pefabloc, in preservation solution for islet isolation. Islet yield before purification was higher in the MK/PFC group compared with the ET-Kyoto with Pefabloc (PK)/PFC group. The stimulation index was higher for the MK/PFC group than for the PK/PFC group. These data suggest that ET-Kyoto with ulinastatin was the better combination for pancreas preservation than ET-Kyoto with Pefabloc. Based on these data, we now use ET-Kyoto solution with ulinastatin for clinical islet transplantation.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007515 Islets of Langerhans Irregular microscopic structures consisting of cords of endocrine cells that are scattered throughout the PANCREAS among the exocrine acini. Each islet is surrounded by connective tissue fibers and penetrated by a network of capillaries. There are four major cell types. The most abundant beta cells (50-80%) secrete INSULIN. Alpha cells (5-20%) secrete GLUCAGON. PP cells (10-35%) secrete PANCREATIC POLYPEPTIDE. Delta cells (~5%) secrete SOMATOSTATIN. Islands of Langerhans,Islet Cells,Nesidioblasts,Pancreas, Endocrine,Pancreatic Islets,Cell, Islet,Cells, Islet,Endocrine Pancreas,Islet Cell,Islet, Pancreatic,Islets, Pancreatic,Langerhans Islands,Langerhans Islets,Nesidioblast,Pancreatic Islet
D009926 Organ Preservation The process by which organs are kept viable outside of the organism from which they were removed (i.e., kept from decay by means of a chemical agent, cooling, or a fluid substitute that mimics the natural state within the organism). Organ Preservations,Preservation, Organ,Preservations, Organ
D010710 Phosphates Inorganic salts of phosphoric acid. Inorganic Phosphate,Phosphates, Inorganic,Inorganic Phosphates,Orthophosphate,Phosphate,Phosphate, Inorganic
D011887 Raffinose A trisaccharide occurring in Australian manna (from Eucalyptus spp, Myrtaceae) and in cottonseed meal. Gossypose,Melitose,Melitriose
D002469 Cell Separation Techniques for separating distinct populations of cells. Cell Isolation,Cell Segregation,Isolation, Cell,Cell Isolations,Cell Segregations,Cell Separations,Isolations, Cell,Segregation, Cell,Segregations, Cell,Separation, Cell,Separations, Cell
D003922 Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence. Diabetes Mellitus, Brittle,Diabetes Mellitus, Insulin-Dependent,Diabetes Mellitus, Juvenile-Onset,Diabetes Mellitus, Ketosis-Prone,Diabetes Mellitus, Sudden-Onset,Diabetes, Autoimmune,IDDM,Autoimmune Diabetes,Diabetes Mellitus, Insulin-Dependent, 1,Diabetes Mellitus, Type I,Insulin-Dependent Diabetes Mellitus 1,Juvenile-Onset Diabetes,Type 1 Diabetes,Type 1 Diabetes Mellitus,Brittle Diabetes Mellitus,Diabetes Mellitus, Insulin Dependent,Diabetes Mellitus, Juvenile Onset,Diabetes Mellitus, Ketosis Prone,Diabetes Mellitus, Sudden Onset,Diabetes, Juvenile-Onset,Diabetes, Type 1,Insulin Dependent Diabetes Mellitus 1,Insulin-Dependent Diabetes Mellitus,Juvenile Onset Diabetes,Juvenile-Onset Diabetes Mellitus,Ketosis-Prone Diabetes Mellitus,Sudden-Onset Diabetes Mellitus
D005466 Fluorocarbons Liquid perfluorinated carbon compounds which may or may not contain a hetero atom such as nitrogen, oxygen or sulfur, but do not contain another halogen or hydrogen atom. This concept includes fluorocarbon emulsions, and fluorocarbon blood substitutes. Perfluorinated and related polyfluorinated chemicals are referred to as PFAS and are defined as chemicals with at least two adjacent carbon atoms, where one carbon is fully fluorinated and the other is at least partially fluorinated. Fluorocarbon,Fluorocarbon Emulsion,Fluorocarbon Emulsions,Fluorotelomer Phosphate Esters,N-Alkyl Perfluoroalkyl Sulfonamido Carboxylates,PFAS Per- and Polyfluoroalkyl Substances,PFC Perfluorinated Chemicals,PFECAs Perfluoropolyether Carboxylic Acids,Per- and Polyfluoroalkyl Substances,Perfluoroalkane Sulfonamides,Perfluoroalkyl Carboxylates,Perfluoroalkyl Ether Carboxylates,Perfluoroalkyl Polyether Carboxylates,Perfluorocarbon,Perfluorocarbons,Perfluoropolyether Carboxylic Acids,Polyfluorocarbons,Fluorinated Telomer Alcohols,Fluoro-Telomer Alcohols,Polyfluorinated Telomer Alcohols,Telomer Fluorocarbons,Acids, Perfluoropolyether Carboxylic,Alcohols, Fluorinated Telomer,Alcohols, Fluoro-Telomer,Alcohols, Polyfluorinated Telomer,Carboxylates, Perfluoroalkyl,Carboxylates, Perfluoroalkyl Ether,Carboxylates, Perfluoroalkyl Polyether,Carboxylic Acids, Perfluoropolyether,Chemicals, PFC Perfluorinated,Emulsion, Fluorocarbon,Emulsions, Fluorocarbon,Esters, Fluorotelomer Phosphate,Ether Carboxylates, Perfluoroalkyl,Fluoro Telomer Alcohols,Fluorocarbons, Telomer,N Alkyl Perfluoroalkyl Sulfonamido Carboxylates,PFAS Per and Polyfluoroalkyl Substances,Per and Polyfluoroalkyl Substances,Perfluorinated Chemicals, PFC,Phosphate Esters, Fluorotelomer,Polyether Carboxylates, Perfluoroalkyl,Sulfonamides, Perfluoroalkane,Telomer Alcohols, Fluorinated,Telomer Alcohols, Polyfluorinated
D005942 Gluconates Derivatives of gluconic acid (the structural formula HOCH2(CHOH)4COOH), including its salts and esters. Copper Gluconate,Gluconate, Copper
D005978 Glutathione A tripeptide with many roles in cells. It conjugates to drugs to make them more soluble for excretion, is a cofactor for some enzymes, is involved in protein disulfide bond rearrangement and reduces peroxides. Reduced Glutathione,gamma-L-Glu-L-Cys-Gly,gamma-L-Glutamyl-L-Cysteinylglycine,Glutathione, Reduced,gamma L Glu L Cys Gly,gamma L Glutamyl L Cysteinylglycine

Related Publications

Hirofumi Noguchi, and Michiko Ueda, and Shuji Hayashi, and Naoya Kobayashi, and Teru Okitsu, and Yasuhiro Iwanaga, and Hideo Nagata, and Xiaoling Liu, and Hiroki Kamiya, and Marlon F Levy, and Shinichi Matsumoto
January 2010, Cell transplantation,
Hirofumi Noguchi, and Michiko Ueda, and Shuji Hayashi, and Naoya Kobayashi, and Teru Okitsu, and Yasuhiro Iwanaga, and Hideo Nagata, and Xiaoling Liu, and Hiroki Kamiya, and Marlon F Levy, and Shinichi Matsumoto
December 2013, Cell medicine,
Hirofumi Noguchi, and Michiko Ueda, and Shuji Hayashi, and Naoya Kobayashi, and Teru Okitsu, and Yasuhiro Iwanaga, and Hideo Nagata, and Xiaoling Liu, and Hiroki Kamiya, and Marlon F Levy, and Shinichi Matsumoto
February 2007, Transplantation,
Hirofumi Noguchi, and Michiko Ueda, and Shuji Hayashi, and Naoya Kobayashi, and Teru Okitsu, and Yasuhiro Iwanaga, and Hideo Nagata, and Xiaoling Liu, and Hiroki Kamiya, and Marlon F Levy, and Shinichi Matsumoto
March 1998, Transplantation proceedings,
Hirofumi Noguchi, and Michiko Ueda, and Shuji Hayashi, and Naoya Kobayashi, and Teru Okitsu, and Yasuhiro Iwanaga, and Hideo Nagata, and Xiaoling Liu, and Hiroki Kamiya, and Marlon F Levy, and Shinichi Matsumoto
March 2021, Xenotransplantation,
Hirofumi Noguchi, and Michiko Ueda, and Shuji Hayashi, and Naoya Kobayashi, and Teru Okitsu, and Yasuhiro Iwanaga, and Hideo Nagata, and Xiaoling Liu, and Hiroki Kamiya, and Marlon F Levy, and Shinichi Matsumoto
March 1998, Transplantation proceedings,
Hirofumi Noguchi, and Michiko Ueda, and Shuji Hayashi, and Naoya Kobayashi, and Teru Okitsu, and Yasuhiro Iwanaga, and Hideo Nagata, and Xiaoling Liu, and Hiroki Kamiya, and Marlon F Levy, and Shinichi Matsumoto
February 2002, Transplantation proceedings,
Hirofumi Noguchi, and Michiko Ueda, and Shuji Hayashi, and Naoya Kobayashi, and Teru Okitsu, and Yasuhiro Iwanaga, and Hideo Nagata, and Xiaoling Liu, and Hiroki Kamiya, and Marlon F Levy, and Shinichi Matsumoto
February 2019, Transplantation,
Hirofumi Noguchi, and Michiko Ueda, and Shuji Hayashi, and Naoya Kobayashi, and Teru Okitsu, and Yasuhiro Iwanaga, and Hideo Nagata, and Xiaoling Liu, and Hiroki Kamiya, and Marlon F Levy, and Shinichi Matsumoto
October 2005, Transplantation proceedings,
Hirofumi Noguchi, and Michiko Ueda, and Shuji Hayashi, and Naoya Kobayashi, and Teru Okitsu, and Yasuhiro Iwanaga, and Hideo Nagata, and Xiaoling Liu, and Hiroki Kamiya, and Marlon F Levy, and Shinichi Matsumoto
September 2022, Transplantation,
Copied contents to your clipboard!